Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

312P - Survival of breast cancer patients with brain metastases treated with radiotherapy in Ontario, Canada: A population-based study

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Radiation Oncology

Tumour Site

Breast Cancer

Presenters

Rania Chehade

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

R. Chehade1, X.Y. Wang2, M.N. Rosen3, A. Sahgal4, S. Das5, R. Saskin6, B. Zhang6, H. Soliman4, K.K. Chan7, K.J. Jerzak1

Author affiliations

  • 1 Division Of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, M5G 1V7 - Toronto/CA
  • 2 Faculty Of Medicine, University of Toronto, M5S 1A8 - Toronto/CA
  • 3 Faculty Of Medicine, University of Ottawa, K1H 8L6 Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021; 27(17): 1943-1958 [DOI: 10.3748/wjg.v27.i17.1943] - Ottawa/CA
  • 4 Department Of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, M4N 3M5 - Toronto/CA
  • 5 Division Of Neurosurgery, St. Michael’s Hospital, University of Toronto, M5B 1W8 - Toronto/CA
  • 6 Institute Of Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto/CA
  • 7 Division Of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto/CA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 312P

Background

Real-world outcomes of patients with breast cancer (BC) brain metastases (BrM) are poorly understood.

Methods

We conducted a retrospective, observational population-based cohort study to assess treatment patterns and outcomes of patients with BC who received radiotherapy for intracranial metastatic disease between January 2009 and December 2019. The primary endpoint was overall survival (OS) before and after adjustment for type of radiotherapy and other potential confounding variables.

Results

88,111 patients with a history of stage I to IV BC were identified, 2.4% (n=2,120) of whom required radiotherapy for BrM during their disease course. Median age at treatment was 53 (45-62). 40.4% of patients had stage I, 32.9% had stage II, 11.9% had stage III and 4.6% had stage IV disease at the time of initial BC diagnosis; stage was unknown for the remaining 10.2% of patients. The most common BC subtype was hormone receptor (HR)+/HER2- (36.9%), with 8.2% of patients having HER2+ and 5.4% having triple-negative disease; subtype was unknown in 49.6% of cases. Whole brain radiotherapy (WBRT) was administered to 82% (n=1738) of patients with BrM while 18% (n=382) were treated with stereotactic radiosurgery (SRS). The median OS from the time of radiotherapy for BC BrM was 5.4 months in the overall population. Median OS for triple-negative, HR+/HER2-, HER2+/HR- and HER2+/HR+ populations was 3.1 months, 4.8 months, 9.4 months and 11.0 months, respectively. Patients treated with SRS had a longer median OS than those treated with WBRT (9.3 months vs 4.6 months, p<0.0001), with lower 30-day mortality (5.2% vs 15.5%, p<0.001). In a multivariable Cox Model, treatment with WBRT (HR 1.76, 95%CI 1.53-2.03) and TNBC subtype (HR 1.57, 95%CI 1.34-1.85) were associated with a shorter OS after adjustment for age, Elixhauser co-morbidity index, income quintile and index year at BC diagnosis.

Conclusions

“Real world” median survival after radiotherapy for BC BrM remains poor. Given that patients treated for BrM with SRS lived longer with a lower risk of 30-day mortality than those treated with WBRT, the use of SRS should be encouraged when clinically indicated.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Dr. Katarzyna J. Jerzak.

Funding

Eli Lilly.

Disclosure

A. Sahgal: Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Varian; Financial Interests, Personal, Advisory Board: BrainLAB; Financial Interests, Personal, Advisory Board: VieCure; Non-Financial Interests, Personal, Member of the Board of Directors: International Stereotactic Radiosurgery Society (ISRS); Non-Financial Interests, Personal, Invited Speaker, co-chair: AO Spine Knowledge Forum Tumor; Financial Interests, Personal, Invited Speaker, educational seminars: Elekta AB; Financial Interests, Personal, Invited Speaker, educational seminars: Accuray Inc.; Financial Interests, Personal, Invited Speaker, educational seminars: Varian; Financial Interests, Personal, Invited Speaker, educational seminars: BrainLAB; Financial Interests, Personal, Invited Speaker, educational seminars: Medtronic Kyphon; Financial Interests, Personal, Research Grant: Elekta AB; Financial Interests, Personal, Other, Travel accommodations/expenses: Elekta; Financial Interests, Personal, Other, Travel accommodations/expenses: Varian; Financial Interests, Personal, Other, Travel accommodations/expenses: BrainLAB; Non-Financial Interests, Personal, Member: Elekta MR Linac Research Consortium; Non-Financial Interests, Personal, Member: Elekta Spine; Non-Financial Interests, Personal, Member: Oligometastases; Non-Financial Interests, Personal, Member: Linac Based SRS Consortia; Financial Interests, Personal, Research Grant: Varian. S. Das: Financial Interests, Personal, Advisory Board, Consultant: AbbVie; Non-Financial Interests, Personal, Advisory Board, Consultant: Xpan Medical; Financial Interests, Personal, Advisory Board, Consultant: Synaptive; Financial Interests, Personal, Advisory Board, Consultant: Omniscient; Financial Interests, Personal, Other, board member: Subcortical Surgery Group; Financial Interests, Personal, Invited Speaker, Past educational seminars: AbbVie; Financial Interests, Personal, Invited Speaker, Past educational seminars: Subcortical Surgery Group; Financial Interests, Personal, Invited Speaker, Past educational seminars: Congress of Neurological Surgeons; Financial Interests, Personal, Invited Speaker, Past educational seminars: Society for NeuroOncology; Financial Interests, Personal, Invited Speaker, Past educational seminars: American Association of Neurological Surgeons; Financial Interests, Personal, Research Grant, Past educational seminars: Alkerme; Financial Interests, Personal, Research Grant, Past educational seminars: Medicenna; Financial Interests, Personal, Other, Travel accommodations/expenses: Subcortical Surgery Group; Financial Interests, Personal, Other, Travel accommodations/expenses: Society for NeuroOncology; Financial Interests, Personal, Other, Travel accommodations/expenses: American Association of Neurological Surgeons; Financial Interests, Personal, Other, Travel accommodations/expenses: Integra; Financial Interests, Personal, Other, Travel accommodations/expenses: Congress of Neurological Surgeons. K.J. Jerzak: Financial Interests, Personal, Advisory Role, speaker/Consultant: Amgen; Financial Interests, Personal, Advisory Role, Speaker/Consultant: AstraZeneca; Financial Interests, Personal, Advisory Role, speaker/Consultant: Apo Biologix; Financial Interests, Personal, Advisory Role, speaker/Consultant: Eli Lilly; Financial Interests, Personal, Advisory Role, speaker/Consultant: Eisai; Financial Interests, Personal, Advisory Role, speaker/Consultant: Genomic Health; Financial Interests, Personal, Advisory Role, Speaker/Consultant: Knight Therapeutics; Financial Interests, Personal, Advisory Role, speaker/Consultant: Merck; Financial Interests, Personal, Advisory Role, speaker/Consultant: Myriad Genetics Inc; Financial Interests, Personal, Advisory Role, speaker/Consultant: Pfizer; Financial Interests, Personal, Advisory Role, speaker/Consultant: Roche; Financial Interests, Personal, Advisory Role, Speaker/Consultant: Purdue Pharma; Financial Interests, Personal, Advisory Role, Speaker/Consultant: Novartis; Financial Interests, Personal, Funding: Eli Lilly; Financial Interests, Personal, Funding: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.